BRIEF published on 10/28/2026 at 06:35, 12 days 19 hours ago Sensorion participates in the 33rd ESGCT Congress Gene Therapy Deafness SENS-601 Sensory ESGCT 2026
BRIEF published on 10/19/2026 at 10:33, 21 days 15 hours ago Sensorion appoints Peter Weber as Chief Medical Officer Appointment Gene Therapy Hearing Loss Sensory Peter Weber
BRIEF published on 10/07/2026 at 07:35, 1 month 2 days ago Louis J. Arcudi III appointed Chief Financial Officer of Sensorion Chief Financial Officer Appointment SENS-601 Sensory Louis J. Arcudi III
PRESS RELEASE published on 10/07/2026 at 07:30, 1 month 2 days ago Inside Information / Other news releases Sensorion appoints Louis J. Arcudi III as Chief Financial Officer. Arcudi brings extensive biopharmaceutical industry experience to the role Chief Financial Officer Biopharmaceutical Industry Financial Leadership Sensorion Louis J. Arcudi III
BRIEF published on 09/23/2026 at 07:35, 1 month 16 days ago Sensorion Reports 2026 Half-Year Results and Updates Financial Results Gene Therapy Sensorion Hearing Loss SENS-601
PRESS RELEASE published on 09/23/2026 at 07:30, 1 month 16 days ago Inside Information / News release on accounts, results Sensorion reports 2026 half-year results, provides corporate update, and announces availability of the half-year report. Progress on gene therapy programs showcased Financial Highlights Gene Therapy Clinical Trial Sensorion 2026 Results
BRIEF published on 09/18/2026 at 07:35, 1 month 21 days ago Sensorion unveils details of the SENS-601 Program Day Gene Therapy Hearing Loss SENS-601 Sensory HearConnex
PRESS RELEASE published on 09/18/2026 at 07:30, 1 month 21 days ago Inside Information / Other news releases Sensorion announces connection details for its SENS-601 Program Day on September 22, 2026, featuring Prof. Christine Petit and Dr. Sharon Cushing. Details available on the Company's website Gene Therapy Sensorion SENS-601 Program Day Connection Details
BRIEF published on 09/16/2026 at 07:35, 1 month 23 days ago Sensorion Submits Initial Public Offering Draft Biotechnology IPO SEC Filing Audiology Sensorion
BRIEF published on 09/16/2026 at 07:35, 1 month 23 days ago Sensorion is considering an initial public offering in the United States Biotechnology Initial Public Offering DRY Sensory Auditory Therapies
Published on 11/09/2026 at 23:10, 2 hours 47 minutes ago Ur-Energy Reports Third Quarter 2026 Results
Published on 11/09/2026 at 23:00, 2 hours 57 minutes ago LNG Energy Group Announces Issuance of Third Partial Revocation Order and Proposed Shares-for-Debt Settlement
Published on 11/09/2026 at 22:32, 3 hours 25 minutes ago Announces Extension for Closing of Private Placement of Convertible Promissory Notes
Published on 11/09/2026 at 22:15, 3 hours 42 minutes ago Goldcliff Announces Closing of the Second and Final Tranche of its "LIFE" Offering and Completion of Drilling at Kettle Valley
Published on 11/10/2026 at 01:20, 36 minutes ago US defence customer steps up orders and first graphene oxide orders secured
Published on 11/09/2026 at 22:54, 3 hours 2 minutes ago EQS-Adhoc: Northern Data Group reports Q3 2026 and raises its FY 2026 revenue outlook communicated on 17 June 2026
Published on 11/09/2026 at 22:10, 3 hours 46 minutes ago Quantinuum to Participate in the Cantor Convergence 4th Annual Crypto, FinTech, AI & Energy Infrastructure Conference
Published on 11/09/2026 at 22:05, 3 hours 52 minutes ago Mayr-Melnhof Karton AG: MM Group to sell majority stake in its Packaging business to KPS Capital Partners and plans a special distribution to shareholders
Published on 11/09/2026 at 18:30, 7 hours 27 minutes ago Air Liquide has successfully issued a CHF 390 million multi-tranche bond
Published on 11/09/2026 at 17:35, 8 hours 22 minutes ago Disclosure of transactions in own shares from November 2 to November 6, 2026
Published on 11/09/2026 at 10:32, 15 hours 25 minutes ago Disclosure of shares outstanding and voting rights - 09.11.2026
Published on 11/09/2026 at 07:00, 18 hours 57 minutes ago bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
